In chronic myelogenous leukemia (CML), SNHG5 up-regulation stimulates imatinib resistance, through down-regulation of miR-205 and up-regulation of ABCC2 (ATP binding cassette subfamily C member 2) (85). Here, SNHG5 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.